BofA Securities Upgrades Biogen (BIIB) to Neutral
Tweet
Share
E-mail
Get Alerts BIIB Hot Sheet
Price: $209.83 -0.39%
Rating Summary:
28 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
28 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
BofA Securities analyst Geoff Meacham upgraded Biogen (NASDAQ: BIIB) from Underperform to Neutral.
For an analyst ratings summary and ratings history on Biogen click here. For more ratings news on Biogen click here.
Shares of Biogen closed at $247.01 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Wolfe Research Upgrades Biogen (BIIB) to Outperform
- Wolfe Research upgrades Biogen, AbbVie on pipeline strength and valuation
- CIBC Upgrades PRO REIT (PRV-U:CN) to Outperformer
Create E-mail Alert Related Categories
UpgradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
